Cilostazol is a quinolone derivative primarily used in the treatment of intermittent claudication associated with early-stage peripheral vascular disease. Intermittent claudication is a condition caused by the narrowing of arteries that supply the legs with oxygenated blood. Patients with intermittent claudication develop pain when walking due to a lack of oxygen-containing blood reaching the operating leg muscles. Cilostazol decreases the pain of intermittent claudication by dilating these arteries, which improves blood flow and oxygen to the legs. Cilostazol is an effective therapy for improving walking distances in patients with intermittent claudication, and the artery disease guidelines of the American College of Cardiology/American Heart Association reference a therapeutic trial of cilostazol. [Level I] Cilostazol has also been shown to be significantly more effective than clopidogrel and aspirin alone for long-term prevention of severe vascular events in patients with a history of transient ischemic attack or non-cardioembolic ischemic stroke.
Cilostazol is a phosphodiesterase III (PDE3) inhibitor. PDE3s are enzymes that utilize a catalytic core to hydrolyze cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP). Phosphodiesterase III enzymes are primarily located within the cardiac sarcoplasmic reticulum, as well as in the smooth muscle of arteries and veins where they are involved in the regulation of cardiac and vascular smooth muscle contractility. Cilostazol exerts its action by inhibiting phosphodiesterase activity and suppressing cAMP degradation. The inhibition of PDE3 allows for a rise in cAMP in platelets and blood vessels. Increased concentrations of cAMP subsequently lead to increased concentrations of the active form of protein kinase A (PKA), and increased PKA is directly related to the inhibition of platelet aggregation. Elevated levels of PKA also exercise a vasodilatory effect on smooth muscle cells by preventing contraction through the inactivation of myosin light-chain kinase. Myosin light-chain kinase normally phosphorylates the light chain of myosin in the presence of calcium and calmodulin which activates myosin to interact with actin. With the inactivation of myosin light-chain kinase by PKA, the myosin-actin interaction cannot occur, and thus, there is an inability to generate smooth muscle contraction.
Cilostazol has also recently demonstrated the ability to reduce plasma triglycerides and increase HDL cholesterol concentrations. The precise mechanisms of cilostazol's ability to lower plasma triglycerides and increase HDL are currently not understood; however, the lipoprotein effects of cilostazol are likely a result of the inhibition of cyclic nucleotide phosphodiesterase with a precipitant elevation of intracellular cAMP. As of now, several possible mechanisms have been proposed by which increased cAMP could result in lowered plasma triglycerides. One possible explanation is the reduction of hepatic triglyceride secretion (either directly or indirectly) by the increased effectiveness of glucagon to inhibit VLDL secretion. Alternatively, increased cAMP levels have demonstrated the ability to promote the release of lipoprotein lipase from rat adipocytes, which could also result in reduced plasma triglycerides.
Cilostazol metabolism occurs extensively in the liver by hepatic cytochrome P450 enzymes (mainly CYP3A4, and to a lesser extent CYP2C19). Two metabolites are primarily active, with one appearing to account for at least half of the pharmacologic activity (PDE3 inhibition) after administration of the drug. Cilostazol is predominately eliminated by urinary excretion of metabolites (74%), with the remainder being excreted fecally (20%).
Cilostazol can be dosed and administered as follows:
For intermittent claudication:
For thrombotic complications of coronary angioplasty:
Cilostazol should be administered orally with water 30 minutes before or 2 hours after meals (breakfast and dinner). A high-fat meal increases absorption, with an approximately 90% increase in peak serum concentration and a 25% increase in plasma concentration of the drug over time. Do not take cilostazol with grapefruit juice as this may impair drug metabolism. Peak pharmacodynamic effects (increased heart rate, antiplatelet activity, decrease in diastolic blood pressure) usually occur within 6 hours. Symptomatic relief of intermittent claudication may be experienced within 2 to 4 weeks; however, it can take up to as to 12 weeks to obtain the optimal therapeutic effect. Dosage of cilostazol can be reduced or discontinued without a rebound phenomenon.
Cilostazol is a generally well-tolerated oral medication. Common side effects of cilostazol therapy reportedly include headache (34%), diarrhea (19%), and palpitations (10%). A slight elevation in heart rate of 5 to 7 beats/min may also occur with the administration of cilostazol. These side effects are noted to be mild to moderate in intensity, ephemeral, or alleviated with symptomatic treatment and seldom demand treatment withdrawal.
Drugs that exhibit vasodilator-type properties generally reduce systemic blood pressure, resulting in a reduction in lower limb perfusion pressure. These agents may also cause a steal of blood from ischemic regions in which blood vessels are already maximally dilated. Therefore, there have been questions regarding the justification for treatment with vasodilators in claudication with absolute contraindication in patients with a history of heart failure. Phosphodiesterase inhibitors have demonstrated decreased survival compared with placebo in patients with class III to IV heart failure, and patients with a history of ischemic heart disease may incur increased risk for exacerbation of angina pectoris or myocardial infarction. Thus, contraindications include the use of cilostazol in these populations.
Cilostazol may induce tachycardia, palpitations, tachyarrhythmia, and/or hypotension. Caution is also necessary when prescribing cilostazol to individuals with atrial or ventricular ectopy and/or those with atrial fibrillation or flutter. Left ventricular outflow tract obstruction is also another observation in patients with sigmoid shaped interventricular septums undergoing cilostazol therapy. Cilostazol has been shown to induce thrombocytopenia or leukopenia, progressing to agranulocytosis when drug administration does not immediately discontinue. Agranulocytosis is reversible with immediate discontinuation of the drug.
Patients with an increased risk for serious cardiac events due to increased heart rate (patients with stable coronary disease) require close monitoring during treatment with cilostazol. Patients also need monitoring for episodes of bleeding and easy bruising, or other signs such as pyrexia and sore throat, which might suggest the early development of blood dyscrasia. A complete blood count is necessary if there is a suspected infection, or if any other clinical evidence suggests blood dyscrasia. If the patient shows any clinical or laboratory evidence of a hematologic abnormality, cilostazol therapy should discontinue immediately.
Caution is necessary when co-administering cilostazol with any other pharmacologic agent that has the potential to reduce blood pressure due to the possibility of an additive hypotensive effect with reflex tachycardia. Dual administration of cilostazol with other antiplatelet drugs also requires caution as there is a risk for unanticipated, prolonged, or excessive bleeding.
There is limited data on acute overdosage with cilostazol in humans. The signs and symptoms of an acute cilostazol overdose can present as a severe headache, diarrhea, hypotension, tachycardia, and possibly cardiac arrhythmia. In the event of an overdose, patients require careful observation and providing supportive treatment. Cilostazol is highly protein-bound and is therefore unlikely to be efficiently removed by hemodialysis or peritoneal dialysis. Emptying the stomach by gastric lavage may be appropriate if needed. The oral lethal dose of cilostazol is over 5.0 g/kg in rats and mice and more than 2.0 g/kg in dogs.
Healthcare professionals such as nurse practitioners, pharmacists, and physicians who plan to use cilostazol should be well aware regarding the indications and contraindications of the drug. Cilostazol's primary use is in the treatment of intermittent claudication, which correlates typically with early-stage peripheral artery disease.
Prescribing clinicians (MDs, DOs, NPs, PAs) should know that the drug is usually administered twice daily as a 100 mg oral dose shortly before or after meals. Consider possible adverse side effects when using cilostazol in patients with a history of supraventricular arrhythmias or heart disease. Additionally, exercise caution when co-administering cilostazol with any other pharmacologic agent that may reduce blood pressure due to the possibility of an additive hypotensive effect and subsequent reflex tachycardia, therefore pharmacists should watch for these interactions and report back to the clinician or nursing. Both pharmacists and nursing can counsel patients on optimal dosing and administration with regard to meals. Patients receiving cilostazol requires close monitoring for tachyarrythmias, hypotension, and/or signs of blood dyscrasia, which will largely be a function of nursing, which can also report these findings to the prescribing clinician. The interprofessional health care team should work collaboratively to ensure patients taking cilostazol obtain regular followup, and the appropriate medical professionals weigh in as needed in the care of these patients. [Level V]
|||Sorkin EM,Markham A, Cilostazol. Drugs [PubMed PMID: 10069409]|
|||Gerhard-Herman MD,Gornik HL,Barrett C,Barshes NR,Corriere MA,Drachman DE,Fleisher LA,Fowkes FGR,Hamburg NM,Kinlay S,Lookstein R,Misra S,Mureebe L,Olin JW,Patel RAG,Regensteiner JG,Schanzer A,Shishehbor MH,Stewart KJ,Treat-Jacobson D,Walsh ME,Halperin JL,Levine GN,Al-Khatib SM,Birtcher KK,Bozkurt B,Brindis RG,Cigarroa JE,Curtis LH,Fleisher LA,Gentile F,Gidding S,Hlatky MA,Ikonomidis J,Joglar J,Pressler SJ,Wijeysundera DN, 2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary. Vascular medicine (London, England). 2017 Jun; [PubMed PMID: 28494710]|
|||Niu PP,Guo ZN,Jin H,Xing YQ,Yang Y, Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. BMJ open. 2016 Mar 17; [PubMed PMID: 26988347]|
|||Ahmad F,Degerman E,Manganiello VC, Cyclic nucleotide phosphodiesterase 3 signaling complexes. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2012 Sep; [PubMed PMID: 22692928]|
|||Shattil SJ,Kashiwagi H,Pampori N, Integrin signaling: the platelet paradigm. Blood. 1998 Apr 15; [PubMed PMID: 9531572]|
|||Abdel-Latif AA, Cross talk between cyclic nucleotides and polyphosphoinositide hydrolysis, protein kinases, and contraction in smooth muscle. Experimental biology and medicine (Maywood, N.J.). 2001 Mar; [PubMed PMID: 11361033]|
|||Kishi H,Ye LH,Nakamura A,Okagaki T,Iwata A,Tanaka T,Kohama K, Structure and function of smooth muscle myosin light chain kinase. Advances in experimental medicine and biology. 1998; [PubMed PMID: 9889833]|
|||Elam MB,Heckman J,Crouse JR,Hunninghake DB,Herd JA,Davidson M,Gordon IL,Bortey EB,Forbes WP, Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, thrombosis, and vascular biology. 1998 Dec; [PubMed PMID: 9848888]|
|||Björnsson OG,Sparks JD,Sparks CE,Gibbons GF, Regulation of VLDL secretion in primary culture of rat hepatocytes: involvement of cAMP and cAMP-dependent protein kinases. European journal of clinical investigation. 1994 Feb; [PubMed PMID: 8206083]|
|||Motoyashiki T,Morita T,Ueki H, Involvement of the rapid increase in cAMP content in the vanadate-stimulated release of lipoprotein lipase activity from rat fat pads. Biological [PubMed PMID: 8951155]|
|||Chapman TM,Goa KL, Cilostazol: a review of its use in intermittent claudication. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2003; [PubMed PMID: 14727939]|
|||Bramer SL,Forbes WP, Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clinical pharmacokinetics. 1999; [PubMed PMID: 10702883]|
|||Reilly MP,Mohler ER 3rd, Cilostazol: treatment of intermittent claudication. The Annals of pharmacotherapy. 2001 Jan; [PubMed PMID: 11197586]|
|||Woo SK,Kang WK,Kwon KI, Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans. Clinical pharmacology and therapeutics. 2002 Apr; [PubMed PMID: 11956507]|
|||Rogers KC,Oliphant CS,Finks SW, Clinical efficacy and safety of cilostazol: a critical review of the literature. Drugs. 2015 Mar; [PubMed PMID: 25758742]|
|||Packer M,Carver JR,Rodeheffer RJ,Ivanhoe RJ,DiBianco R,Zeldis SM,Hendrix GH,Bommer WJ,Elkayam U,Kukin ML, Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. The New England journal of medicine. 1991 Nov 21; [PubMed PMID: 1944425]|
|||Bangalore S,Singh A,Toklu B,DiNicolantonio JJ,Croce K,Feit F,Bhatt DL, Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open heart. 2014; [PubMed PMID: 25332804]|
|||Umazume T,Funabashi N,Inoue T,Nishi T,Shimizu T,Jo K,Ishikawa T,Nakamura Y,Miyazaki A,Kobayashi Y, Adverse effects of cilostazol on left ventricular function in a patient with a sigmoid shaped interventricular septum. International journal of cardiology. 2013 May 25; [PubMed PMID: 22995418]|
|||Anderson JL,Halperin JL,Albert NM,Bozkurt B,Brindis RG,Curtis LH,DeMets D,Guyton RA,Hochman JS,Kovacs RJ,Ohman EM,Pressler SJ,Sellke FW,Shen WK, Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Apr 2; [PubMed PMID: 23457117]|